Logo image of AKRO

AKERO THERAPEUTICS INC (AKRO) Stock Fundamental Analysis

NASDAQ:AKRO - Nasdaq - US00973Y1082 - Common Stock - Currency: USD

47.57  +9.43 (+24.72%)

Premarket: 47.03 -0.54 (-1.14%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AKRO. AKRO was compared to 561 industry peers in the Biotechnology industry. While AKRO seems to be doing ok healthwise, there are quite some concerns on its profitability. AKRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AKRO had negative earnings in the past year.
In the past year AKRO has reported a negative cash flow from operations.
AKRO had negative earnings in each of the past 5 years.
In the past 5 years AKRO always reported negative operating cash flow.
AKRO Yearly Net Income VS EBIT VS OCF VS FCFAKRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -23.31%, AKRO is in the better half of the industry, outperforming 75.22% of the companies in the same industry.
With an excellent Return On Equity value of -24.86%, AKRO belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
Industry RankSector Rank
ROA -23.31%
ROE -24.86%
ROIC N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
AKRO Yearly ROA, ROE, ROICAKRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

AKRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKRO Yearly Profit, Operating, Gross MarginsAKRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, AKRO has more shares outstanding
Compared to 5 years ago, AKRO has more shares outstanding
Compared to 1 year ago, AKRO has an improved debt to assets ratio.
AKRO Yearly Shares OutstandingAKRO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AKRO Yearly Total Debt VS Total AssetsAKRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 30.32 indicates that AKRO is not in any danger for bankruptcy at the moment.
AKRO's Altman-Z score of 30.32 is amongst the best of the industry. AKRO outperforms 97.33% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that AKRO is not too dependend on debt financing.
AKRO has a Debt to Equity ratio (0.03) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 30.32
ROIC/WACCN/A
WACCN/A
AKRO Yearly LT Debt VS Equity VS FCFAKRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

AKRO has a Current Ratio of 16.80. This indicates that AKRO is financially healthy and has no problem in meeting its short term obligations.
AKRO's Current ratio of 16.80 is amongst the best of the industry. AKRO outperforms 91.62% of its industry peers.
AKRO has a Quick Ratio of 16.80. This indicates that AKRO is financially healthy and has no problem in meeting its short term obligations.
AKRO's Quick ratio of 16.80 is amongst the best of the industry. AKRO outperforms 91.62% of its industry peers.
Industry RankSector Rank
Current Ratio 16.8
Quick Ratio 16.8
AKRO Yearly Current Assets VS Current LiabilitesAKRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

AKRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.19%.
EPS 1Y (TTM)-17.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AKRO will show a very strong growth in Earnings Per Share. The EPS will grow by 22.21% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.32%
EPS Next 2Y-11.89%
EPS Next 3Y-9.22%
EPS Next 5Y22.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKRO Yearly Revenue VS EstimatesAKRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B
AKRO Yearly EPS VS EstimatesAKRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKRO Price Earnings VS Forward Price EarningsAKRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKRO Per share dataAKRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as AKRO's earnings are expected to decrease with -9.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.89%
EPS Next 3Y-9.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AKRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKERO THERAPEUTICS INC

NASDAQ:AKRO (5/20/2025, 8:00:00 PM)

Premarket: 47.03 -0.54 (-1.14%)

47.57

+9.43 (+24.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners89.04%
Inst Owner Change16.57%
Ins Owners1.79%
Ins Owner Change1.06%
Market Cap3.79B
Analysts85.56
Price Target80.07 (68.32%)
Short Float %9.55%
Short Ratio5.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.43%
Min EPS beat(2)9.09%
Max EPS beat(2)15.77%
EPS beat(4)3
Avg EPS beat(4)5.64%
Min EPS beat(4)-13.96%
Max EPS beat(4)15.77%
EPS beat(8)5
Avg EPS beat(8)2.68%
EPS beat(12)8
Avg EPS beat(12)5.88%
EPS beat(16)10
Avg EPS beat(16)5.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20.21%
EPS NQ rev (1m)4.67%
EPS NQ rev (3m)13.67%
EPS NY rev (1m)4.36%
EPS NY rev (3m)12.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.5
P/tB 3.5
EV/EBITDA N/A
EPS(TTM)-3.75
EYN/A
EPS(NY)-4.69
Fwd EYN/A
FCF(TTM)-3.31
FCFYN/A
OCF(TTM)-3.3
OCFYN/A
SpS0
BVpS13.6
TBVpS13.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.31%
ROE -24.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.8
Quick Ratio 16.8
Altman-Z 30.32
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-11.32%
EPS Next 2Y-11.89%
EPS Next 3Y-9.22%
EPS Next 5Y22.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-50.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.59%
EBIT Next 3Y-15.09%
EBIT Next 5YN/A
FCF growth 1Y-179.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-178.59%
OCF growth 3YN/A
OCF growth 5YN/A